Next |
home / stock / rvxcf / rvxcf message board
Subject | By | Source | When |
---|---|---|---|
Anyone have any idea what this company is | big orange | investorshub | 07/16/2020 5:32:26 PM |
With all that has been shown in the | cabel | investorshub | 04/21/2020 3:01:14 PM |
I think the only plan is survival. | noretreat | investorshub | 04/21/2020 2:45:10 PM |
Any news about the future plans for this company? | big orange | investorshub | 04/21/2020 2:37:04 PM |
69 cents. tempting, but holding off on | noretreat | investorshub | 03/12/2020 7:18:24 PM |
some will use this pop as an exit | noretreat | investorshub | 02/03/2020 4:17:21 PM |
Yes! Much quicker than expected! | cabel | investorshub | 02/03/2020 1:44:11 PM |
BRIEF-Resverlogix Receives US FDA Breakthrough Therapy Designation For Apabetalo | noretreat | investorshub | 02/03/2020 12:40:17 PM |
But it doesnt really matter what the analyst | noretreat | investorshub | 02/02/2020 7:33:37 PM |
As far as I can tell so far | noretreat | investorshub | 02/02/2020 7:33:00 PM |
What do analysts say about the secondary analysis? | big orange | investorshub | 02/01/2020 9:57:08 PM |
Seeing a clear path to commercialization at the | jstiltz22 | investorshub | 01/13/2020 5:19:24 PM |
Interesting secondary analysis released today | noretreat | investorshub | 01/13/2020 3:39:19 PM |
The sad truth is that BetOnMace was a | noretreat | investorshub | 12/13/2019 10:48:47 PM |
The statement in this release was optimistic to | noretreat | investorshub | 12/11/2019 9:38:59 PM |
This ones down about 40% the last couple | noretreat | investorshub | 12/11/2019 9:37:45 PM |
Resverlogix Announces Change to its Board of Directors CALGARY, | Phoenix300 | investorshub | 12/11/2019 1:32:47 PM |
cognitive results pres. | noretreat | investorshub | 12/06/2019 1:50:49 PM |
ambiguous but holy cow!!! | noretreat | investorshub | 12/06/2019 1:51:07 AM |
Thanks. Time will tell. | big orange | investorshub | 12/01/2019 6:59:04 PM |
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of a...
2024-03-27 17:08:02 ET Developing safe, epigenetic therapeutics for people suffering from chronic illnesses Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions...
2024-03-27 17:08:02 ET The future of drug development Resverlogix is committed to developing epigenetic therapies for the benefit of patients with chronic disease. Their current clinical program focuses on advancing their lead compound ( apabetalone) and evaluating its th...